Study met the primary endpoint and all secondary endpoints, highly consistent with rapid response from the INTEGUMENT-1 and INTEGUMENT-2 pivotal trials For the primary endpoint, 25.4% of children ...
58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4 Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a ...
Full data results will be presented at future medical conferences and in peer-reviewed journals. The INTEGUMENT-1 study met the primary endpoint and all secondary endpoints. Topline results were ...
Arcutis Biotherapeutics has announced promising results from its Phase 3 INTEGUMENT-OLE study concerning the investigational ZORYVE cream for treating atopic dermatitis (AD). The long-term study ...
Today, the FDA approved roflumilast cream 0.15% (Zorvye; Arcutis Biotherapeutics) for the treatment of mild to moderate atopic dermatitis in patients 6 years and older. Roflumilast cream 0.15% is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results